Type

The Evidence Type refers to the type of clinical (or biological) association described by the Evidence Item’s clinical summary.

Understanding Evidence Types

Six Evidence Types are currently supported: Predictive (i.e. Therapeutic), Diagnostic, Prognostic, Predisposing, Oncogenic, and Functional. Each Evidence Type describes the clinical or biological effect a Molecular Profile (MP) has on the following: therapeutic response (Predictive), determining a patient’s diagnosis or disease subtype (Diagnostic), predicting disease progression or patient survival (Prognostic), disease susceptibility (Predisposing), or biological alterations relevant to a cancer phenotype (Oncogenic) or protein function (Functional). Selecting an Evidence Type has implications on available selections for Significance, which are detailed on the Evidence Significance page.

Type	Icon	Definition
Diagnostic		Evidence pertains to a variant’s impact on patient diagnosis (cancer subtype)
Predictive		Evidence pertains to a variant’s effect on therapeutic response
Prognostic		Evidence pertains to a variant’s impact on disease progression, severity, or patient survival.
Predisposing		Evidence pertains to a germline Molecular Profile’s role in conferring susceptibility to disease (including pathogenicity evaluations)
Oncogenic		Evidence pertains to a somatic variant’s involvement in tumor pathogenesis as described by the Hallmarks of Cancer.
Functional		Evidence pertains to a variant that alters biological function from the reference state.

Extensive documentation for curating Evidence types is provided on the Curating Evidence page. Be sure to closly study the examples for each type.